After Britain passed legislation protecting children from “gender-affirming care,” the government is now halting the use of puberty blockers and hormone treatments for minors.
The move marks a significant step in the country’s move away from the “gender-affirming care” model for children experiencing gender dysphoria.
The treatments have grown as a subject of controversy over the past decade, with critics pointing out the lack of evidence that they provide a healthy solution for those confused about their gender. They point out that using these treatments is more likely to have a damaging effect on children – especially after they become adults.
British Secretary of State for Health and Social Care Victoria Atkins made the announcement on X, saying she has “taken bold action to protect children following the Cass Review, using emergency powers to ban puberty blockers for new treatments of gender dysphoria from private clinics and for all purposes from overseas prescribers into Great Britain.”
Today I have taken bold action to protect children following the Cass Review, using emergency powers to ban puberty blockers for new treatments of gender dysphoria from private clinics and for all purposes from overseas prescribers into Great Britain.https://t.co/pLX7x0bH0n
— Victoria Atkins (@VictoriaAtkins) May 29, 2024
In the post, Atkins referenced a groundbreaking report compiled by Dr. Hilary Cass, a pediatrician whose studies highlighted the fact that puberty blockers and hormone treatments do not provide a benefit for most of the children who take them. It also exposed deep flaws in prior studies suggesting that they are an effective remedy. Her findings sent shockwaves through the medical community and even prompted threats against her.
“Our children deserve healthcare that is compassionate, caring and careful, and that is what a Conservative Government would deliver,” Atkins posted in the thread.
The legislation, known as “The National Health Service” was brought before Parliament on May 29. It restricts the prescription of puberty blockers to minors.
The legislation highlights parts of Cass’ report, noting that her investigation found that the drugs not only provide no real mental health benefits to children suffering from gender dysphoria but also compromise bone density.
This ban reflects a significant paradigm shift in how Britain looks at gender dysphoria. It represents the realization that the “gender-affirming care” model likely causes more harm than good – especially when used on minors. The country, along with other European nations, is looking at talk therapy and other alternatives as a more viable solution.
This is an excellent step forward that could eventually have an impact on the United States. People are realizing that these treatments are not what progressives have portrayed them to be, and they have caused irreversible harmful effects in far too many people whose parents were tricked into allowing them to undergo these medications.
Cass’ revelations have played a significant role in exposing the lies told by those seeking to trans children. But there are even more studies emerging further illustrating the harms caused by “gender-affirming care.” These studies, combined with the slew of lawsuits being filed by detransitioners against the medical facilities who conned them into the treatments, will eventually bring about a reckoning that could result in the cessation of these treatments.
